The revenue beat and positive gross margin milestone are overshadowed by an EPS miss and widening net loss. The restructuring (13% headcount reduction) is a CERTAIN-PRESENT negative event (costs incurred now) that partially offsets the FUTURE-AVOIDED benefit of ~$15M annual savings starting 2027. The maintained FY2026 guidance of $120-135M revenue provides a floor, but cash burn of ~$71M/quarter implies only ~3 quarters of runway at current pace. Monitor Q2 2026 for gross margin trajectory and whether the restructuring accelerates the path to profitability. Pipeline catalysts (MS, lupus nephritis data) are distant (2027-2028) and provide no near-term support.
Price Chart
Executive Summary
Autolus Therapeutics reported Q1 2026 AUCATZYL net product revenue of $26.2M, up 192% YoY from $9.0M, achieving its first positive gross margin of $1.6M. However, the EPS of -$0.27 missed the consensus estimate of -$0.26 by 4.2%, and the net loss widened to $71.6M from $70.2M. The company reiterated FY2026 revenue guidance of $120-135M and confirmed a restructuring plan (13% workforce reduction) announced 15 days prior, which is expected to save ~$15M annually starting in 2027. The combination of a revenue beat, positive gross margin milestone, and maintained guidance is offset by an EPS miss, rising SG&A costs, and ongoing cash burn ($229.4M cash, sufficient into Q4 2027).
Key Financial Metrics
Key Facts
- Q1 2026 AUCATZYL net product revenue of $26.2M, up 192% YoY from $9.0M
- First-ever positive gross margin of $1.6M (gross profit), compared to a loss in all prior quarters
- EPS of -$0.27 missed consensus of -$0.26 by 4.2%
- Net loss widened to $71.6M from $70.2M YoY
- SG&A expenses increased 35% YoY to $39.9M, including one-time restructuring costs
- Cash, cash equivalents and marketable securities at $229.4M, down from $300.7M at Dec 31, 2025
- FY2026 AUCATZYL net product revenue guidance reiterated at $120-135M (up from $74M in 2025)
- Restructuring plan (13% workforce reduction) announced April 29, 2026, expected to save ~$15M annually from 2027
- Cash runway projected into Q4 2027 based on current operating plans
- Pipeline on track: CATULUS (pediatric ALL) data end-2027, LUMINA (lupus nephritis) data 2028, BOBCAT (MS) initial data end-2026
Financial Impact
Revenue beat of ~$0.1M vs consensus ($26.2M vs $26.1M); EPS miss of -$0.01 vs consensus (-$0.27 vs -$0.26); positive gross margin milestone of $1.6M; cash burn of ~$71M in Q1
Risk Factors
- Cash burn rate of ~$71M/quarter implies runway only into Q4 2027 without additional financing
- SG&A costs rising 35% YoY to $39.9M, outpacing revenue growth and signaling commercialization cost overruns
- Restructuring charges of ~$8M will hit H1 2026 earnings, further pressuring EPS
- Dependence on single product AUCATZYL for all revenue; pipeline data years away
- EPS miss extends a pattern of Street misses (4 of last 5 quarters per Nasdaq reference)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001730463-26-000058 |
| Document: autlex-991pr140526.htm | 0001730463-26-000058 |
| Document: autlex-992cp140526.htm | 0001730463-26-000058 |
| Document: 0001730463-26-000058-index-headers.html | 0001730463-26-000058 |
| Document: 0001730463-26-000058-index.html | 0001730463-26-000058 |
| Document: 0001730463-26-000058.txt | 0001730463-26-000058 |
| 8-K Data (Synthetic) | 0001730463-26-000058 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 12, 2026 20d ago | S-3 | $1.94 $1.94 | · 0.00% | ▼ −0.11% | $1.78 (−8.25%) |
Aug 11, 2026 7w ago | 8-K | $2.33 $2.29 | ▼ −1.72% | ▼ −1.31% | $1.78 (−23.61%) |
Aug 3, 2026 8w ago | 8-K | $1.82 $2.07 | ▲ +13.74% | ▲ +11.71% | $1.78 (−2.20%) |
Aug 3, 2026 8w ago | 8-K | $1.82 $2.07 | ▲ +13.74% | ▲ +11.71% | $1.78 (−2.20%) |
Jun 12, 2026 16w ago | Press Release | $1.56 $1.51 | ▼ −3.21% | ▼ −3.88% | $1.78 (+14.10%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.56 $1.53 | ▲ +1.92% | ▲ +2.36% | $1.78 (−14.10%) |
Jun 9, 2026 16w ago | 8-K | $1.46 $1.50 | ▼ −2.74% | ▼ −0.33% | $1.78 (−21.92%) |
May 21, 2026 19w ago | Press Release | $1.70 $1.84 | ▲ +8.24% | ▲ +6.58% | $1.78 (+4.71%) |
May 14, 2026 20w ago | 8-K | $1.59 $1.65 | ▲ +3.77% | ▲ +4.49% | $1.78 (+11.95%) |
May 14, 2026 20w ago | Press Release | $1.59 $1.65 | ▲ +3.77% | ▲ +4.49% | $1.78 (+11.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access